Revenue growth is due to growth in Teva's US generics business, the company's main market, among other things due to sales of ...

Teva Pharmaceutical Industries raised its 2024 revenue and earnings guidance on Wednesday after beating third-quarter profit ...

As other biopharma giants have divested their generics units to focus on the development and commercialization of innovative ...

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the ...

TEVA reports better-than-expected third-quarter results, beating both earnings and sales estimates. However, the stock declines 7%.

In terms of liquidity and interest, the mean open interest for Teva Pharmaceutical Indus options trades today is 8263.67 with ...

South Dakota will receive almost $300,000 as part of a settlement with global health company Apotex and Teva Pharmaceuticals ...

For many years, Copaxone was the main driver of Teva's sales growth, which the Israel-based pharma fought hard to protect, including by releasing a long-acting version of the drug. It was a $4 ...

high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. Receive News & Ratings for Teva Pharmaceutical ...

Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...